

DESCRIPTION


Species Reactivity	Human
Specificity	Detects human Serpin E1/PAI-1 in ELISAs and Western blots. In sandwich immunoassays, less than 0.2% cross-reactivity with recombinant human (rh) Serpin A1, rhSerpin A3, rhSerpin A4, rhSerpin A5, and rhSerpin F2 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant human Serpin E1/PAI-1 (R&D Systems, Catalog # 1786-PI) Ser22-Pro402 Accession # P05121
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	1 µg/mL	See Below
Human Serpin E1/PAI-1 Sandwich Immunoassay		Reagent
ELISA Capture	2-8 µg/mL	Human Serpin E1/PAI-1 Antibody (Catalog # MAB1786)
ELISA Detection	0.1-0.4 µg/mL	Human Serpin E1/PAI-1 Biotinylated Antibody (Catalog # BAF1786)
Standard		Recombinant Human Serpin E1/PAI-1 (Catalog # 1786-PI)

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI-1 is the principal inhibitor of urokinase-type plasminogen activator (uPA) and tissue-type PA (1, 2). As important regulators of extracellular matrix remodeling, uPA and PAI-1 play a major role in many processes such as angiogenesis, tumor invasion and obesity (2-4). For example, uPA and PAI-1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer (5). The human PAI-1 is initially synthesized as 402 amino acid precursor with a N-terminal signal peptide (6, 7). PAI-1 may exist in one of two possible conformations, designated as active or latent (8). The purified recombinant human (rh) PAI-1 is active against rhuPA. The heterogeneity at the N-terminus of the purified rhPAI-1 has been observed before for both the recombinant and native proteins (9).

References:

1. Silverman, G.A. *et al.* (2001) *J. Biol. Chem.* **276**:33293.
2. Stefansson, S. *et al.* (2003) *Curr. Pharm. Des.* **9**:1545.
3. Duffy, M.J. (2002) *Clin. Chem.* **48**:1194.
4. Juhan-Vague, I. *et al.* (2003) *J. Thromb. Haemost.* **1**:1575.
5. Harbeck, N. *et al.* (2002) *Clin. Breast Cancer* **3**:196.
6. Pannekoek, H. *et al.* (1986) *EMBO J.* **5**:2539.
7. Ginsburg, D. *et al.* (1986) *J. Clin. Invest.* **78**:1673.
8. Wang, Z. *et al.* (1996) *Biochemistry* **35**:16443.
9. Stromqvist, M. *et al.* (1994) *Protein Expr. Purif.* **5**:309.

